Evaluation of clinical, pathological and genetic data of endometrial cancer cases with microsatellite instability

Endometrial cancer, the most common gynecological cancer; In 2013, the Cancer Genome Atlas (TCGA) analyzed the molecular genetic basis of endometrial cancer development and identified four molecular subclasses based on mutation load and copy number changes. Studies have shown that molecular markers in these subgroups are stronger prognostic markers than the histopathological features of the tumor. The aim of this study was to determine the frequency of MSI in the tumor tissues of patients who underwent hysterectomy at Hacettepe University, Department of Obstetrics and Gynecology between January 1, 2019 and March 30, 2021 and whose pathology resulted in endometrial cancer, and to examine the effects of treatments applied on patients with MSI tumors on the prognosis; It is aimed to evaluate patients who meet the test criteria in terms of LS and to contribute to the literature by combining clinical, pathological and genetic data. There were 174 patients in total in the study group. MMR deficiency was detected in 61 (35.1%) of these patients, and no deficiency was observed in 112 (64.4%) patients. When the effect of deficiency of MMR on treatment was examined, no independent variable that made a statistically significant difference was observed. Lynch Syndrome was detected in 4 patients in total. Genetic counseling was offered to these patients. As a result, molecular classification will become the basis of molecular subgroup adjuvant treatment approaches and individualized treatments in the coming years. Keywords: Endometrial Cancer, Molecular Classification, Mismatch Repair, Lynch Syndrome